%0 Journal Article
%T History of Infection Prior to Hematopoietic Stem Cell Transplant in the Recipient as a Risk Factor to Develop Acute Graft versus Host Disease
%A Alberto Olaya-Vargas
%A Iv¨¢n Castorena-Villa
%A Martin P¨¦rez-Garc¨ªa
%A Gerardo Hern¨¢ndez Lop¨¦z-Hern¨¢ndez
%A Nideshda Ram¨ªrez-Uribe
%A Hayde¨¦ Salazar-Rosales
%J Journal of Cancer Therapy
%P 327-335
%@ 2151-1942
%D 2019
%I Scientific Research Publishing
%R 10.4236/jct.2019.104026
%X <strong>Background: </strong><span><span><span style=\"font-family:&quot;\"><span style=\"font-family:Verdana;\">Acute graft-versus-host disease (aGVHD) is the most
frequent and severe complication after allogeneic hematopoietic stem cell
transplantation (HSCT). </span><b><span><span style=\"font-family:Verdana;\">Objective:</span><i> </i></span></b><span style=\"font-family:Verdana;\">To determine if a history of prior infection in the allogeneic
HSTC recipient is a risk factor to develop aGVHD. </span><b><span style=\"font-family:Verdana;\">Methods: </span></b><span style=\"font-family:Verdana;\">A
retrospective cohort study based on data collected from the </span><span style=\"font-family:Verdana;\">Department
of Hematopoietic Stem Cell Transplantation at the Instituto Nacional de Pediatr¨ªa
(INP) from January 1998 to December 2016 was performed to identify if prior
infection was a predictive risk factor for aGVHD. </span><b><span style=\"font-family:Verdana;\">Results:</span></b> <span style=\"font-family:Verdana;\">27
patients developed aGVHD (36.4%). Median time to aGVHD presentation was 82 days
(9 to 273 days). Most patients developed grade III aGVHD. Following the
multivariate analysis </span><span style=\"font-family:Verdana;\">peripheral blood &gt; bone marrow (OR 12.3; p &lt;
0.001), cell dose &gt; 8.3 ¡Á 10</span><sup><span style=\"font-family:Verdana;\">6</span></sup><span style=\"font-family:Verdana;\">/kg (OR 7.1; p = 0.05), peripheral
blood (OR: 11.4; p &lt; 0.001), infection 3 months prior to allogeneic
transplant (OR: 4.5; p &lt; 0.03) and CMV infection in the recipient (OR: 4.68;
p &lt; 0.03) were significant. </span><b><span style=\"font-family:Verdana;\">Conclusions:</span></b><span style=\"font-family:Verdana;\"> Either bacterial infection or CMV infection
in the recipient w</span></span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">as </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">significant risk factor
within the aGVHD recipients</span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">; </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">it is important to
consider these factors for patients that are going to receive an allogeneic
HSCT.</span></span></span>
%K Allogeneic HSCT
%K Complications
%K Acute GVHD
%K HSCT Infections
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=92126